BINEX Co., Ltd. (KOSDAQ:053030)

South Korea · Delayed Price · Currency is KRW

6,410.00

-80.00 (-1.23%)

Oct 2, 2026, 3:30 PM KST

Market Cap	204.14B -60.0%
Revenue (ttm)	157.28B +2.7%
Net Income	-29.27B
EPS	-918.93
Shares Out	31.85M
PE Ratio	n/a
Forward PE	36.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,089
Open	6,530.00
Previous Close	6,490.00
Day's Range	6,400.00 - 6,590.00
52-Week Range	5,500.00 - 16,800.00
Beta	0.68
Analysts	Buy
Price Target	12,550.00 (+95.79%)
Est. Earnings	Nov 13, 2026

About BINEX

BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. The company engages in cell line and process development, and analytical method production development. It is also involved in cell cultivation and microbial fermentation modalities process production. In addition, the company offers chemical pharmaceutical products. BINEX Co., Ltd. was founded in 1957 and is headquartered in Busan, South Korea. [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1957

Employees 720

Stock Exchange KOSDAQ

Ticker Symbol 053030

Full Company Profile

Financial Performance

In 2025, BINEX's revenue was 168.47 billion, an increase of 29.55% compared to the previous year's 130.05 billion. Losses were -3.23 billion, -90.80% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 053030 stock is "Buy." The 12-month stock price target is ₩12,550, which is an increase of 95.79% from the latest price.

Price Target

₩12,550

(95.79% upside)

Analyst Consensus: Buy

Stock Forecasts